✦ LIBER ✦

A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C.

✍ Scribed by M Pardo; I Castillo; H Oliva; A Fernandez-Flores; R Barcena; MA de Peuter; V Carreno

Book ID: 118686746
Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 181 KB
Volume: 26
Category: Article
ISSN: 0270-9139
DOI: 10.1053/jhep.1997.v26.pm0009362378

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A pilot study of recombinant interleukin

A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C

✍ M Pardo; I Castillo; H Oliva; A Fernandez-Flores; R Barcena; M A de Peuter; V Ca 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB 👁 1 views

The optimal and safer interleukin-2 (IL-2) dose for treatment of chronic hepatitis C virus (HCV) infection has been studied in 33 HCV-RNA positive patients with chronic hepatitis C. Patients were randomly allocated to receive 5 days per week during 12 weeks IL-2 doses of: 0.9 MIU (n = 10), 1.8 MIU (

Pilot study of recombinant human interle

Pilot study of recombinant human interleukin 2 for chronic type B hepatitis

✍ Shinichi Kakumu; Akihiko Fuji; Kentaro Yoshioka; Hirofumi Tahara; Yoshiyuki Ohta 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 541 KB

Recombinant human interleukin 2 was administered to 10 patients with chronic type B hepatitis as a part of a pilot study to evaluate its antiviral activity. Patients received 1 to 3 x 10' units per day of interleukin 2 for 21 to 28 days, and all completed the treatment schedule. During therapy, seru

Treatment of children with chronic hepat

Treatment of children with chronic hepatitis C with recombinant interferon-α: A pilot study

✍ Mercedes Ruiz-Moreno; Maria José Rua; Inmaculada Castillo; Maria Dolores García- 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 1 views

Twelve children with chronic non-A, non-B hepatitis were entered in a pilot trial of recombinant interferon-alpha. Although all the children had hepatitis C virus RNA in serum, only five had antibodies against this virus. Children received 3 MU/m2 body surface area interferon-alpha 3 times/wk for 6

Ribavirin treatment for chronic hepatiti

Ribavirin treatment for chronic hepatitis D: a pilot study

✍ A. Garripoli; V. DI Marco; R. Cozzolongo; C. Costa; A. Smedile; A. Fabiano; F. B 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB

A pilot study of 2′,3′-dideoxyinosine fo

A pilot study of 2′,3′-dideoxyinosine for the treatment of chronic hepatitis B

✍ Michael W. Fried; Julia C. Korenman; Adrian M. Di Bisceglie; Yoon Park; Jeanne G 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB 👁 1 views

The nucleoside analog 2',3'-dideoxyinosine, currently being used to treat patients infected with the human immunodeficiency virus, has been shown to inhibit viral replication in certain cell culture systems of hepatitis B virus and the duck model of chronic hepatitis B infection. We studied the effe

A pilot study of ribavirin therapy for c

A pilot study of ribavirin therapy for chronic hepatitis C

✍ Adrian M. di Bisceglie; Michiko Shindo; Tse-Ling Fong; Michael W. Fried; Mark G. 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 541 KB

Interferon-alpha therapy is of proven efficacy in chronic hepatitis C, but it is not universally effective and may be associated with intolerable side effects. Ribavirin is a nucleoside analog with a broad spectrum of antiviral action. We conducted an uncontrolled pilot study of ribavirin therapy in